Influenza vaccine effectiveness among adults aged ≥60 years in northeastern Zhejiang Province, China, 2021–2024

Zhao Yu, Xinyu Liu, Jiayun Fu, Xueping Yang, Lu Fang, Yanru Chu, Jialie Jin, Zenghao Xu, Yanli Cao, Jinren Pan, S L Liu, Xiaofei Fu, Tianfeng He, Hangjie ZhangFrontiers in Public Health 2026 · DOI

TL;DR

This study evaluated the real-world effectiveness of influenza vaccines in older adults (≥60 years) in Zhejiang Province, China, over three flu seasons. The findings indicate moderate protection, but highlight significant variations in effectiveness based on influenza subtype, age, and season, with notably lower protection in the oldest age group (≥80 years).

What Problem Does This Paper Address?

Influenza poses a significant threat to older adults, leading to severe illness and complications. Despite this, vaccination coverage in this demographic remains suboptimal in China, partly due to the vaccine not being part of the national immunization program and requiring out-of-pocket payment. While some regions in China have started offering free vaccination programs for older adults, there's a need to understand the real-world effectiveness of these programs, especially across different influenza seasons and viral subtypes. This study aims to fill this gap by evaluating the influenza vaccine effectiveness (VE) in adults aged 60 and above in northeastern Zhejiang Province, a region that has progressively expanded its free vaccination program for this age group.

Methods

The researchers employed a test-negative design (TND), a standard epidemiological approach for evaluating vaccine effectiveness in real-world settings. This design involves comparing influenza virus detection rates between individuals who received the vaccine and those who did not, among patients presenting with influenza-like illness (ILI).

Here's a breakdown of their approach:

  • Study Population: Adults aged 60 and above presenting with ILI at sentinel surveillance hospitals in Jiaxing and Ningbo, Zhejiang Province, between October 2021 and April 2024. ILI was defined by specific symptom criteria (fever ≥37.5°C, cough or sore throat, and symptom onset ≤7 days).
  • Data Collection: Standardized questionnaires captured demographic information, vaccination history (including current and previous season vaccination), and clinical data. Vaccination status was primarily confirmed using the Zhejiang Provincial Immunization Registry.
  • Laboratory Confirmation: Respiratory specimens were tested for influenza virus nucleic acids using real-time reverse transcription polymerase chain reaction (RT-PCR) to confirm influenza infection and identify subtypes.
  • Statistical Analysis: Multivariable logistic regression models were used to assess factors associated with vaccination status and influenza positivity. This allowed for the estimation of adjusted odds ratios (aORs) and subsequent calculation of vaccine effectiveness (VE) as 100% × (1 - aOR). The analysis controlled for potential confounders like sex, age group, underlying medical conditions, and influenza season.

Datasets

The study utilized data collected from ILI patients presenting at sentinel surveillance hospitals in Ningbo and Jiaxing cities of Zhejiang Province between October 2021 and April 2024. This data was supplemented by information from the Zhejiang Provincial Immunization Registry for vaccination verification. No new datasets were introduced.

Key Insights and Ideas

  • Age Matters, A Lot: The most striking finding is the significant decline in vaccine effectiveness with increasing age. While the vaccine shows good protection for those aged 60-69, its efficacy diminishes considerably for those 70-79 and is notably limited for individuals 80 and older. This suggests that immunosenescence (age-related decline in immune function) plays a crucial role in how well older adults respond to the vaccine.
  • Subtype and Season Variability: Influenza vaccine effectiveness is not a static number. It fluctuates based on the circulating influenza strains (subtypes) and the specific influenza season. This highlights the ongoing challenge of matching vaccine strains to circulating viruses and the dynamic nature of influenza epidemiology.
  • Moderate Overall Protection: Despite the variations, the vaccine still offers moderate protection against influenza infection for the overall group of adults aged 60 and above. This underscores the continued importance of vaccination as a public health strategy for this vulnerable population.
  • Repeated Vaccination's Role: The study found no significant difference in protection between those vaccinated only in the current season and those vaccinated repeatedly. This suggests that while consistent vaccination is important, the immediate protection from the current season's vaccine is a key factor.

Key Results

  • Overall VE: The study found an overall influenza vaccine effectiveness (VE) of 47.21% (95% CI: 35.38 to 56.88%) among adults aged ≥60 years.
  • Subtype-Specific VE:
    • H1N1: 55.81% (95% CI: 34.83 to 70.03%)
    • H3N2: 40.72% (95% CI: 23.30 to 54.18%)
    • B/Victoria: 55.16% (95% CI: 21.77 to 74.30%)
  • Age-Stratified VE:
    • 60-69 years: 70.34% (95% CI: 41.47 to 84.98%)
    • 70-79 years: 49.48% (95% CI: 34.41 to 61.09%)
    • ≥80 years: 38.34% (95% CI: 10.35 to 57.60%)
  • Vaccination Coverage: The influenza vaccination coverage in the current season among the study participants was 33.14%.

Limitations and Future Work

The authors acknowledge several limitations:

  • Geographic Specificity: The data was collected from sentinel hospitals in only two cities in Zhejiang Province, which may limit the generalizability of findings to other regions or the entire country.
  • Selection Bias: Sentinel surveillance systems might underrepresent individuals with very mild or asymptomatic infections who do not seek medical care.
  • Small Sample Sizes for Subtypes/Seasons: Some specific subtype-season strata had very few positive cases, leading to unstable VE estimates with wide confidence intervals. This is particularly true for the A/H1N1 estimates in the 2023-2024 season.
  • Lack of Detailed Viral Genetic Data: The unavailability of detailed local viral genetic characterization data prevented a precise assessment of the antigenic match between vaccine strains and circulating viruses.

For future work, the authors recommend large-scale, multi-center, and long-term real-world studies to develop more targeted and differentiated vaccination policies for older adults. This could include exploring strategies to enhance vaccine effectiveness in the oldest age groups and better understanding the impact of repeated vaccinations.

Summary updated

Abstract

Influenza vaccination provides moderate protection for adults aged ≥60 years, with effectiveness varying by subtype, age, and season, particularly limited in the older population aged ≥80 years.
BibTeX
@inproceedings{yu2026influenza,
  author = {Zhao Yu and Xinyu Liu and Jiayun Fu and Xueping Yang and Lu Fang and Yanru Chu and Jialie Jin and Zenghao Xu and Yanli Cao and Jinren Pan and S L Liu and Xiaofei Fu and Tianfeng He and Hangjie Zhang},
  title = {{Influenza vaccine effectiveness among adults aged ≥60 years in northeastern Zhejiang Province, China, 2021–2024}},
  booktitle = {Frontiers in Public Health},
  year = {2026},
  doi = {10.3389/fpubh.2025.1730158},
}
Figure